| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 1157.9 | 1159.6 | 1055.5 |
| Other income | 35.3 | 34.3 | 17.5 |
| Total income | 1193.2 | 1193.9 | 1073.1 |
| Profit before exceptional items & tax | 123.0 | 117.8 | 66.9 |
| Exceptional items | -1.8 | -18.2 | 8.2 |
| Profit before tax | 121.2 | 99.6 | 75.1 |
| Net profit | 81.3 | 67.7 | 149.6 |
| Operating margin | 10.2% | 8.3% | 7.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -45.70% |
|---|---|
| Net profit, quarter on quarter | +20.10% |
| Revenue, year on year | +9.70% |
NSE results filing, NSE: AKUMS. Figures extracted from the filing.
Akums Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹826.50
- Market cap
- ₹13,009 Cr
- Revenue (annual)
- ₹4,359 Cr
- Net profit (annual)
- ₹255.2 Cr
- P/E (TTM)
- 44.6×Sector 47.4×
- Promoter holding
- 75.26%+0.00% QoQ
- FII holding
- 1.91%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Akums Drugs & Pharmaceuticals Ltd
All →Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals received an ESG rating of 65 for FY2025-26 from NSE Sustainability Ratings & Analytics Limited. The rating was assigned voluntarily based on publicly available information.
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals Limited has cancelled its participation in the Antique Healthcare Investor Conference scheduled for August 25, 2026, due to unavoidable medical reasons.
Akums Drugs & Pharmaceuticals Earnings Call Transcript: Key Takeaways
Akums reported strong Q1FY27 performance with 13.9% revenue growth and 56.1% PAT increase. Results were driven by a robust 18.6% growth in the CDMO segment and improved API pricing.
Akums Drugs & Pharmaceuticals Other Announcement
The company filed its quarterly shareholding pattern for the period ended September 30, 2025, in compliance with SEBI LODR regulations.
Akums Drugs & Pharmaceuticals Investor Presentation: Key Takeaways
Akums reported strong Q1 FY27 results with 13.9% revenue growth and 56.1% PAT growth. Strategy focuses on CDMO volume growth and expanding skincare/wellness via the Oriflame India manufacturing acquisition.
Akums Drugs & Pharmaceuticals Results Update
Akums Drugs reported Q1 FY27 consolidated revenue of ₹1,167 crore, reflecting 13.9% year-on-year growth. PAT rose to ₹101 crore compared to ₹65 crore in Q1 FY26.